Treating patients with moderate-to-severe psoriasis vulgaris

被引:2
作者
Kessler, Timothy R. [1 ]
机构
[1] Pinnacle Silverton Skin Inst, Dermatol, Grand Blanc, MI 48439 USA
来源
JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS | 2022年 / 35卷 / 03期
关键词
psoriasis vulgaris; skin disease; biologic therapy; interleukin-19; interleukin-23; inflammatory; PLAQUE PSORIASIS; CLINICAL-RESPONSE; CONTROLLED-TRIAL; PHASE-III; TILDRAKIZUMAB; ETANERCEPT; PREVALENCE; EFFICACY; ANTIBODY; SAFETY;
D O I
10.1097/01.JAA.0000819580.10133.b1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Psoriasis vulgaris is a common inflammatory disease of adults and children. Affected patients often are incorrectly diagnosed, undertreated, or not treated at all. The relapsing course of psoriasis negatively affects a patient's quality of life. The condition is associated with social isolation, anxiety, and depression, and can harm personal relationships and employment status. Psoriasis may have a significant psychologic and socioeconomic effect throughout a patient's life. Skin involvement is the most prominent symptom of this disease; however, understanding that psoriasis is a chronic, multisystem inflammatory disease is essential to proper treatment. Patients with mild-to-moderate psoriasis can control their disease primarily with topical medications or phototherapy. However, when used as monothcrapy or combined with phototherapy, topical medication can be inadequate to treat moderate-to-severe psoriasis. Biologic agents offer treatment options with many benefits for controlling psoriasis vulgaris, whether given as monotherapy or combined with topical or systemic medications.
引用
收藏
页码:28 / 35
页数:8
相关论文
共 24 条
[1]   Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis [J].
Amin, M. ;
Darji, K. ;
No, D. J. ;
Wu, J. J. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) :1627-1632
[2]   Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity [J].
Arican, O ;
Aral, M ;
Sasmaz, S ;
Ciragil, P .
MEDIATORS OF INFLAMMATION, 2005, (05) :273-279
[3]   Joint AADeNPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures [J].
Elmets, Craig A. ;
Korman, Neil J. ;
Prater, Elizabeth Farley ;
Wong, Emily B. ;
Rupani, Reena N. ;
Kivelevitch, Dario ;
Armstrong, April W. ;
Connor, Cody ;
Cordoro, Kelly M. ;
Davis, Dawn M. R. ;
Elewski, Boni E. ;
Gelfand, Joel M. ;
Gordon, Kenneth B. ;
Gottlieb, Alice B. ;
Kaplan, Daniel H. ;
Kavanaugh, Arthur ;
Kiselica, Matthew ;
Kroshinsky, Daniela ;
Lebwohl, Mark ;
Leonardi, Craig L. ;
Lichten, Jason ;
Lim, Henry W. ;
Mehta, Nehal N. ;
Paller, Amy S. ;
Parra, Sylvia L. ;
Pathy, Arun L. ;
Siegel, Michael ;
Stoff, Benjamin ;
Strober, Bruce ;
Wu, Jashin J. ;
Hariharan, Vidhya ;
Menter, Alan .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (02) :432-470
[4]   Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy [J].
Elmets, Craig A. ;
Lim, Henry W. ;
Stoff, Benjamin ;
Connor, Cody ;
Cordoro, Kelly M. ;
Lebwohl, Mark ;
Armstrong, April W. ;
Davis, Dawn M. R. ;
Elewski, Boni E. ;
Gelfand, Joel M. ;
Gordon, Kenneth B. ;
Gottlieb, Alice B. ;
Kaplan, Daniel H. ;
Kavanaugh, Arthur ;
Kiselica, Matthew ;
Kivelevitch, Dario ;
Korman, Neil J. ;
Kroshinsky, Daniela ;
Leonardi, Craig L. ;
Lichten, Jason ;
Mehta, Nehal N. ;
Paller, Amy S. ;
Parra, Sylvia L. ;
Pathy, Arun L. ;
Prater, Elizabeth A. Farley ;
Rupani, Reena N. ;
Siegel, Michael ;
Strober, Bruce E. ;
Wong, Emily B. ;
Wu, Jashin J. ;
Hariharan, Vidhya ;
Menter, Alan .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (03) :775-804
[5]   ACITRETIN VERSUS ETRETINATE IN PSORIASIS - CLINICAL AND PHARMACOKINETIC RESULTS OF A GERMAN MULTICENTER STUDY [J].
GOLLNICK, H ;
BAUER, R ;
BRINDLEY, C ;
ORFANOS, CE ;
PLEWIG, G ;
WOKALEK, H ;
HOTING, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1988, 19 (03) :458-468
[6]   Efficacy of etanercept in an integrated multistudy database of patients with psoriasis [J].
Gordon, K ;
Korman, N ;
Frankel, E ;
Wang, H ;
Jahreis, A ;
Zitnik, R ;
Chang, T .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) :S101-S111
[7]   Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study [J].
Gordon, Kenneth B. ;
Langley, Richard G. ;
Leonardi, Craig ;
Toth, Darryl ;
Menter, M. Alan ;
Kang, Sewon ;
Heffernan, Michael ;
Miller, Bruce ;
Hamlin, Regina ;
Lim, Liberata ;
Zhong, Jianhua ;
Hoffman, Rebecca ;
Okun, Martin M. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (04) :598-606
[8]   Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris [J].
Gottlieb, AB ;
Masud, S ;
Ramamurthi, R ;
Abdulghani, A ;
Romano, P ;
Chaudhari, U ;
Dooley, LT ;
Fasanmade, AA ;
Wagner, CL .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (01) :68-75
[9]  
Griffi ths CE, LANCET
[10]  
Gudjonsson JE, 2019, FITZPATRICKS DERMATO, Vninth